Cargando…
2021–2022 Drug Updates: Investigational Therapeutics in the Pipeline
During JADPRO Live 2022, Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP, discussed investigational therapeutic agents in the drug development pipeline. Dr. Moore highlighted agents that represent either a new drug class, a novel mechanism of action, a rethinking of how to approach treating a diseas...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Harborside Press LLC
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184839/ https://www.ncbi.nlm.nih.gov/pubmed/37197720 http://dx.doi.org/10.6004/jadpro.2023.14.3.11 |
| _version_ | 1785042220959662080 |
|---|---|
| author | Moore, Donald C. |
| author_facet | Moore, Donald C. |
| author_sort | Moore, Donald C. |
| collection | PubMed |
| description | During JADPRO Live 2022, Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP, discussed investigational therapeutic agents in the drug development pipeline. Dr. Moore highlighted agents that represent either a new drug class, a novel mechanism of action, a rethinking of how to approach treating a disease, or those that have recently received FDA Breakthrough Designation status that advanced practitioners should be aware of. |
| format | Online Article Text |
| id | pubmed-10184839 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Harborside Press LLC |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101848392023-05-16 2021–2022 Drug Updates: Investigational Therapeutics in the Pipeline Moore, Donald C. J Adv Pract Oncol Meeting Reports During JADPRO Live 2022, Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP, discussed investigational therapeutic agents in the drug development pipeline. Dr. Moore highlighted agents that represent either a new drug class, a novel mechanism of action, a rethinking of how to approach treating a disease, or those that have recently received FDA Breakthrough Designation status that advanced practitioners should be aware of. Harborside Press LLC 2023-04 2023-04-01 /pmc/articles/PMC10184839/ /pubmed/37197720 http://dx.doi.org/10.6004/jadpro.2023.14.3.11 Text en © 2023 Harborside™ https://creativecommons.org/licenses/by-nc-nd/3.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Meeting Reports Moore, Donald C. 2021–2022 Drug Updates: Investigational Therapeutics in the Pipeline |
| title | 2021–2022 Drug Updates: Investigational Therapeutics in the Pipeline |
| title_full | 2021–2022 Drug Updates: Investigational Therapeutics in the Pipeline |
| title_fullStr | 2021–2022 Drug Updates: Investigational Therapeutics in the Pipeline |
| title_full_unstemmed | 2021–2022 Drug Updates: Investigational Therapeutics in the Pipeline |
| title_short | 2021–2022 Drug Updates: Investigational Therapeutics in the Pipeline |
| title_sort | 2021–2022 drug updates: investigational therapeutics in the pipeline |
| topic | Meeting Reports |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184839/ https://www.ncbi.nlm.nih.gov/pubmed/37197720 http://dx.doi.org/10.6004/jadpro.2023.14.3.11 |
| work_keys_str_mv | AT mooredonaldc 20212022drugupdatesinvestigationaltherapeuticsinthepipeline |